Pharmacokinetics of glutamate-oxaloacetate transaminase and glutamate-pyruvate transaminase and their blood glutamate-lowering activity in naïve rats

Neurochemical Research

Volumn 37, Issue 10, 2012, Pages 2198-2205

  Boyko, Matthew ^a   Stepensky, David ^a   Gruenbaum, Benjamin F ^a   Gruenbaum, Shaun E ^b   Melamed, Israel ^a   Ohayon, Sharon ^a   Glazer, Michael ^a   Shapira, Yoram ^a   Zlotnik, Alexander ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Glutamate oxaloacetate transaminase and glutamate pyruvate transaminase enzymes; Neuroprotective activity in traumatic brain injury and stroke; Pharmacokinetics and glutamate lowering activity

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLUTAMIC ACID; SODIUM CHLORIDE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINO ACID BLOOD LEVEL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD; CEREBROVASCULAR ACCIDENT; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG ELIMINATION; EXTRACELLULAR FLUID; GLUTAMATE LOWERING ACTIVITY; MALE; MAXIMUM PLASMA CONCENTRATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TRAUMATIC BRAIN INJURY;

ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; GLUTAMATES; MALE; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA; RATTUS; SUS;

EID: 84866736057     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-012-0843-9     Document Type: Article

References (33)

1. Laurer HL, Lenzlinger PM, McIntosh TK (2000) Models of traumatic brain injury. Eur J Trauma 26:95-100
2. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J (2010) Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation 121(7):e46-e215. doi:10.1161/ CIRCULATIONAHA. 109.192667
3. Zauner A, Bullock R, Kuta AJ, Woodward J, Young HF (1996) Glutamate release and cerebral blood flow after severe human head injury. Acta Neurochir Suppl 67:40-44
4. Castillo J, Davalos A, Naveiro J, Noya M (1996) Neuroexcitatory amino acids and their relation to infarct size and neurological deficit in ischemic stroke. Stroke 27(6):1060-1065
5. Castillo J, Davalos A, Noya M (1997) Progression of ischaemic stroke and excitotoxic aminoacids. Lancet 349(9045):79-83. doi: 10.1016/S0140-6736(96) 04453-4
6. Johnston MV, Trescher WH, Ishida A, Nakajima W (2001) Neurobiology of hypoxic-ischemic injury in the developing brain. Pediatr Res 49(6):735-741
7. Shaw PJ, Forrest V, Ince PG, Richardson JP, Wastell HJ (1995) CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients. Neurodegeneration 4(2):209-216
8. Spranger M, Krempien S, Schwab S, Maiwald M, Bruno K, Hacke W (1996) Excess glutamate in the cerebrospinal fluid in bacterial meningitis. J Neurol Sci 143(1-2):126-131
9. Ferrarese C, Aliprandi A, Tremolizzo L, Stanzani L, De Micheli A, Dolara A, Frattola L (2001) Increased glutamate in CSF and plasma of patients with HIV dementia. Neurology 57(4):671-675
10. Koura SS, Doppenberg EM, Marmarou A, Choi S, Young HF, Bullock R (1998) Relationship between excitatory amino acid release and outcome after severe human head injury. Acta Neurochir Suppl 71:244-246
11. Zhang H, Zhang X, Zhang T, Chen L (2001) Excitatory amino acids in cerebrospinal fluid of patients with acute head injuries. Clin Chem 47(8):1458-1462
12. O'Kane RL, Martinez-Lopez I, DeJoseph MR, Vina JR, Hawkins RA (1999) Na(+)-dependent glutamate transporters (EAAT1, EAAT2, and EAAT3) of the blood-brain barrier. A mechanism for glutamate removal. J Biol Chem 274(45):31891-31895
13. Teichberg VI, Cohen-Kashi-Malina K, Cooper I, Zlotnik A (2009) Homeostasis of glutamate in brain fluids: an accelerated brain-to-blood efflux of excess glutamate is produced by blood glutamate scavenging and offers protection from neuropathologies. Neuroscience 158(1):301-308. doi:10.1016/j.neuroscience.2008.02.075
14. Zlotnik A, Gurevich B, Tkachov S, Maoz I, Shapira Y, Teichberg VI (2007) Brain neuroprotection by scavenging blood glutamate. Exp Neurol 203(1):213-220. doi:10.1016/j.expneurol.2006.08.021
15. Zlotnik A, Gurevich B, Cherniavsky E, Tkachov S, Matuzani-Ruban A, Leon A, Shapira Y, Teichberg VI (2008) The contribution of the blood glutamate scavenging activity of pyruvate to its neuroprotective properties in a rat model of closed head injury. Neurochem Res 33(6):1044-1050. doi:10.1007/s11064-007- 9548-x
16. Zlotnik A, Gruenbaum SE, Artru AA, Rozet I, Dubilet M, Tkachov S, Brotfain E, Klin Y, Shapira Y, Teichberg VI (2009) The neuroprotective effects of oxaloacetate in closed head injury in rats is mediated by its blood glutamate scavenging activity: evidence from the use of maleate. J Neurosurg Anesthesiol 21(3):235-241. doi:10.1097/ANA.0b013e3181a2bf0b
17. Zlotnik A, Klin Y, Kotz R, Dubilet M, Boyko M, Ohayon S, Shapira Y, Teichberg VI (2010) Regulation of blood L-glutamate levels by stress as a possible brain defense mechanism. Exp Neurol 224(2):465-471. doi:10.1016/j.expneurol.2010.05.009
18. Castellanos M, Sobrino T, Pedraza S, Moldes O, Pumar JM, Silva Y, Serena J, Garcia-Gil M, Castillo J, Davalos A (2008) High plasma glutamate concentrations are associated with infarct growth in acute ischemic stroke. Neurology 71(23):1862-1868. doi:10.1212/01.wnl.0000326064.42186.7e
19. Boyko M, Zlotnik A, Gruenbaum BF, Gruenbaum SE, Ohayon S, Kuts R, Melamed I, Regev A, Shapira Y, Teichberg VI (2011) Pyruvate's blood glutamate scavenging activity contributes to the spectrum of its neuroprotective mechanisms in a rat model of stroke. Eur J Neurosci 34(9):1432-1441. doi:10.1111/j.1460-9568.2011.07864.x
20. Campos F, Rodriguez-Yanez M, Castellanos M, Arias S, Perez-Mato M, Sobrino T, Blanco M, Serena J, Castillo J (2011) Blood levels of glutamate oxaloacetate transaminase are more strongly associated with good outcome in acute ischaemic stroke than glutamate pyruvate transaminase levels. Clin Sci (Lond) 121(1): 11-17. doi:10.1042/CS20100427
21. Campos F, Sobrino T, Ramos-Cabrer P, Argibay B, Agulla J, Perez-Mato M, Rodriguez-Gonzalez R, Brea D, Castillo J (2011) Neuroprotection by glutamate oxaloacetate transaminase in ischemic stroke: an experimental study. J Cereb Blood Flow Metab 31(6):1378-1386. doi:10.1038/jcbfm.2011.3
22. Campos F, Sobrino T, Ramos-Cabrer P, Castellanos M, Blanco M, Rodriguez-Yanez M, Serena J, Leira R, Castillo J (2011) High blood glutamate oxaloacetate transaminase levels are associated with good functional outcome in acute ischemic stroke. J Cereb Blood Flow Metab 31(6):1387-1393. doi:10.1038/jcbfm.2011.4
23. Gottlieb M, Wang Y, Teichberg VI (2003) Blood-mediated scavenging of cerebrospinal fluid glutamate. J Neurochem 87(1): 119-126
24. Graham LT Jr, Aprison MH (1966) Fluorometric determination of aspartate, glutamate, and gamma-aminobutyrate in nerve tissue using enzymic methods. Anal Biochem 15(3):487-497
25. Zhang Y, Huo M, Zhou J, Xie S (2010) PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed 99(3):306-314. doi:10.1016/j.cmpb.2010.01.007
26. Teichberg VI (2011) GOT to rid the body of excess glutamate. J Cereb Blood Flow Metab 31(6):1376-1377. doi:10.1038/jcbfm.2011.46
27. Zlotnik A, Ohayon S, Gruenbaum BF, Gruenbaum SE, Mohar B, Boyko M, Klin Y, Sheiner E, Shaked G, Shapira Y, Teichberg VI (2011) Determination of factors affecting glutamate concentrations in the whole blood of healthy human volunteers. J Neurosurg Anesthesiol 23(1):45-49. doi:10.1097/ANA. 0b013e3181f82a8f
28. Jusko WJ, Ko HC (1994) Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 56(4):406-419
29. Klin Y, Zlotnik A, Boyko M, Ohayon S, Shapira Y, Teichberg VI (2010) Distribution of radiolabeled l-glutamate and d-aspartate from blood into peripheral tissues in naive rats: significance for brain neuroprotection. Biochem Biophys Res Commun 399(4): 694-698. doi:10.1016/j.bbrc.2010.07.144
30. Ahlstrom C (2011) Modelling of tolerance and rebound in normal and diseased rats. Ph.D thesis. University of Gothenburg
31. Teichberg VI (2007) From the liver to the brain across the bloodbrain barrier. Proc Natl Acad Sci USA 104(18):7315-7316
32. Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, Cianfrogna J, Doran AC, Doran SD, Gibbs JP, Hosea N, Liu J, Nelson FR, Szewc MA, Van Deusen J (2005) Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of bloodbrain barrier permeability, plasma protein binding, and brain tissue binding. J Pharmacol Exp Ther 313(3):1254-1262. doi: 10.1124/jpet.104.079319
33. Hammarlund-Udenaes M, Friden M, Syvanen S, Gupta A (2008) On the rate and extent of drug delivery to the brain. Pharm Res 25(8):1737-1750. doi:10.1007/s11095-007-9502-2